VivoSeq
Other

Camrelizumab

0

Pipeline Programs↗

7

Active Trials↗

1

Companies Involved↗

Camrelizumab is an early-stage landscape with 0 programs across 1 company. The most active players are Shanghai YingLi Pharmaceutical Co. Ltd..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai YingLi Pharmaceutical Co. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Unknown status14 · 64%
Recruiting5 · 23%
Active, not recruiting2 · 9%
Completed1 · 5%

Clinical Trials

Trial Activity

22 trials

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05139095·70 enrolled
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
Recruiting·—·Phase 2·NCT04888429·28 enrolled
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06172205·262 enrolled
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
Recruiting·SSun Yat-sen University·Phase 2·NCT07238881·30 enrolled
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05412589·35 enrolled
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05198609·214 enrolled
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT04483284·28 enrolled
Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
Completed·PPeking Union Medical College Hospital·Phase 2·NCT04047017·20 enrolled
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
Unknown status·SSun Yat-sen University·Phase 2·NCT05093140·30 enrolled
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Unknown status·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1·NCT05429398·118 enrolled
Camrelizumab Combined With Apatinib Mesylate
Unknown status·HHenan Cancer Hospital·N/A·NCT05380986·500 enrolled
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04303741·46 enrolled
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Unknown status·ZZhongda Hospital·N/A·NCT04559607·188 enrolled
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04291092·63 enrolled
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04683198·69 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)